TY - JOUR
T1 - Glioblastoma and ABO blood groups
T2 - Further evidence of an association between the distribution of blood group antigens and brain tumours
AU - Allouh, Mohammed Z.
AU - Al Barbarawi, Mohammed M.
AU - Hiasat, Mohammad Y.
AU - Al-Qaralleh, Mohammed A.
AU - Ababneh, Emad I.
N1 - Funding Information:
In GB, Carter et al.13observed no significant Conclusions difference in the distribution of blood group antigens In conclusion, we have demonstrated an association between GB patients and controls from the Oxford between the distribution of ABO blood group antigens region in the United Knigdom. Turowski and Czochra14, and the incidence of GB in Jordanians. Specifically, we on the other hand, detected a higher frequency of group show that individuals with group A are at a higher risk A, and a lower frequency of group O, in GB patients of developing GB, and individuals with group O are at from Poland. In a recent study, Akca et al.20 reported a lower risk of developing GB. These findings provide that the most common blood group in GB patients from further evidence to support a role for ABO blood group Turkey was group A. However, there was no significant antigens in the development of brain tumours. However, difference in the distribution of blood group antigens the present study was limited by the fact that we were with that of the general population, given that group A is unable to analyse the A1 and A2 subtypes; further the most frequent blood group in the Turkish population. clinical and experimental investigations are, therefore, In our opinion, the discrepancies between these findings warranted to confirm this relationship between GB and are due to variations in the type and size of the study different blood group subtypes. populations. The underlying mechanism(s) linking ABO Funding blood groups with cancer risk are unclear. However, This study was approved and supported by the several hypotheses have been proposed, including Deanship of Research at JUST (grant n. 223/2015). a modulatory role of ABO blood group antigens on several inflammatory and adhesion molecules, which Authorship contributionsSrl are important for tumourigenesis21,22. Further studies MZA designed the study, performed the statistical have suggested that the structural similarity between analyses and wrote the manuscript. MMA and MYH ABO blood group antigens (especially type A) and contributed to the study conception and collected the several tumour antigens may prevent the immune system data related to GB and accidental trauma patients. MAQ from recognising and destroying tumour cells, which and EIA collected the data related to the blood donor could result in a greater risk of cancer development and matched control groups. and progression22,23. In addition, some authors have proposed a mechanism whereby an indirect role of The Authors declare no conflicts of interest. ABO blood group antigens on cancer risk is mediated Servizi through the von Willebrand factor (vWF)21,24. VWF is References a circulating plasma glycoprotein that is secreted by 1) Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, vascular endothelial cells to promote platelet adhesion 2) Anand P, Kunnumakkara AB,Sundaram C, et al. Cancer is 2012. CACancer J Clin 2015; 65: 87-108. to the sub-endothelium at sites of vascular injury. It also a preventable disease that requires major lifestyle changes. acts as a carrier for coagulation factor VIII24. There is a Pharm Res 2008; 25: 2097-116. well-documented association between the distribution of 3) Garber JE, Offit K. Hereditary cancer ABO blood group antigens and plasma concentrations 4) Franchini M, Liumbruno GM. ABO blood group andsyndromes. J Clin Oncol 2005; 23: 276-92. of vWF25,26. Specifically, individuals with non-O blood neurodegenerative disorders: more than a casual association. SIMTI groups have significantly higher levels of plasma vWF Blood Transfus 2016; 14: 158-9.
Publisher Copyright:
© 2017 SIMTI Servizi Srl.
PY - 2017
Y1 - 2017
N2 - Background. Glioblastoma is a highly malignant brain tumour that usually leads to death. Several studies have reported a link between the distribution of ABO blood group antigens and a risk of developing specific types of cancer, although no consensus has been reached. This study aims to investigate the relationship between the distribution of ABO blood group antigens and the incidence of glioblastoma. Materials and methods. The study cohort consisted of 115 glioblastoma patients who were diagnosed at King Abdullah University Hospital, Jordan, between 2004 and 2015. Three different patient populations made up three control groups and these were selected from among patients at the same institution between 2014 and 2015 as follows: 3,847 healthy blood donors, 654 accidental trauma patients admitted to the Departments of Neurosurgery and Orthopaedics, and 230 age- and sexmatched control subjects recruited blindly from the Departments of Paediatrics and Internal Medicine. Results. There was a significant association between the distribution of ABO blood group antigens and the incidence of glioblastoma. Post hoc residual analysis revealed that individuals with group A had a higher than expected chance of developing glioblastoma, while individuals with group O had a lower than expected chance. Furthermore, individuals with group A were found to be at a 1.62- to 2.28-fold increased risk of developing glioblastoma compared to individuals with group O. Discussion. In the present study, we demonstrate that, in Jordan, individuals with group A have an increased risk of developing glioblastoma, while individuals with group O have a reduced risk. These findings suggest that the distribution of ABO blood group antigens is associated with a risk of brain tumours and may play an important role in their development. However, further clinical and experimental investigations are required to confirm this association.
AB - Background. Glioblastoma is a highly malignant brain tumour that usually leads to death. Several studies have reported a link between the distribution of ABO blood group antigens and a risk of developing specific types of cancer, although no consensus has been reached. This study aims to investigate the relationship between the distribution of ABO blood group antigens and the incidence of glioblastoma. Materials and methods. The study cohort consisted of 115 glioblastoma patients who were diagnosed at King Abdullah University Hospital, Jordan, between 2004 and 2015. Three different patient populations made up three control groups and these were selected from among patients at the same institution between 2014 and 2015 as follows: 3,847 healthy blood donors, 654 accidental trauma patients admitted to the Departments of Neurosurgery and Orthopaedics, and 230 age- and sexmatched control subjects recruited blindly from the Departments of Paediatrics and Internal Medicine. Results. There was a significant association between the distribution of ABO blood group antigens and the incidence of glioblastoma. Post hoc residual analysis revealed that individuals with group A had a higher than expected chance of developing glioblastoma, while individuals with group O had a lower than expected chance. Furthermore, individuals with group A were found to be at a 1.62- to 2.28-fold increased risk of developing glioblastoma compared to individuals with group O. Discussion. In the present study, we demonstrate that, in Jordan, individuals with group A have an increased risk of developing glioblastoma, while individuals with group O have a reduced risk. These findings suggest that the distribution of ABO blood group antigens is associated with a risk of brain tumours and may play an important role in their development. However, further clinical and experimental investigations are required to confirm this association.
KW - ABO blood group system
KW - Brain tumours
KW - Cancer
KW - Glioblastoma
UR - http://www.scopus.com/inward/record.url?scp=85031927157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031927157&partnerID=8YFLogxK
U2 - 10.2450/2016.0041-16
DO - 10.2450/2016.0041-16
M3 - Article
C2 - 27416574
AN - SCOPUS:85031927157
VL - 15
SP - 543
EP - 547
JO - Blood Transfusion
JF - Blood Transfusion
SN - 1723-2007
IS - 6
ER -
